Neuland Lab Peer Comparison

NSE: NEULANDLAB | BSE: 524558

₹21,505.00

₹155.00 (0.73%)

As on 01-Oct-2026IST

Market cap

₹27,580 Cr

Revenue (TTM)

₹2,372 Cr

P/E Ratio

55.4

P/B Ratio

13.6

Div. Yield

0.2 %

Edit

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Market cap (₹ Cr)	27,580	36,872	16,849	14,385	13,556
Revenue (₹ Cr)	2,372	9,683	2,590	1,108	676
Net Profit (₹ Cr)	497.77	1,018.97	603.02	270.18	183.60
Net Margin (%)	20.72	10.47	22.63	23.29	26.06
RoE (%)	28.49	21.30	19.61	14.45	22.72
Price to Earnings	55.41	36.46	27.94	52.24	74.22
Price-To-Book	13.64	7.05	4.83	6.94	14.67

Income Statement (₹ Cr)

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Operating Revenue	2,371.81	9,683.45	2,590.40	1,108.39	675.61
Total Income	2,402.61	9,730.84	2,664.23	1,159.90	704.48
Total Expenditure	1,608.91	7,739.53	1,753.71	720.01	442.67
EBITDA	762.90	1,943.92	836.69	388.38	232.94
Depreciation	98.11	425.10	78.88	74.78	15.56
EBIT	664.79	1,518.82	757.81	313.60	217.38
Interest	26.33	148.45	5.43	0.26	7.96
Other Income	30.80	47.39	73.83	51.50	28.87
Exceptional Items	0.00	-27.85	-25.66	-3.28	0.00
Profit before Tax	669.26	1,389.91	800.55	361.56	238.30
Provision for Tax	171.48	370.94	197.53	91.39	54.69
Profit after Tax	497.77	1,018.97	603.02	270.18	183.60

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Shareholder's Funds	1,874.47	4,950.03	3,332.13	2,017.06	883.34
Minority Interest	0.00	-7.58	0.00	2.51	-0.97
Non-Current Liabilities	345.47	723.57	142.73	50.51	74.82
Current Liabilities	710.20	3,912.24	508.04	169.08	201.96
Total Liabilities	2,930.14	9,514.48	4,157.10	2,231.79	1,174.38

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Non-Current Assets	1,290.62	3,392.16	1,321.38	957.22	477.92
Current Assets	1,483.13	5,612.10	2,649.36	1,250.11	623.97
Total Assets	2,930.14	9,514.48	4,157.10	2,231.79	1,174.38
Total Debt*	196.61	1,204.08	0.00	0.00	148.29
Net Current Assets	772.93	1,699.86	2,141.33	1,081.04	422.01
Contingent Liabilities	13.18	258.92	4.82	3.76	--

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Cash From Operating Activities	346.68	943.55	565.41	266.88	69.55
Cash Flow from Investing Activities	-423.73	-1,193.06	-570.15	-142.72	-330.93
Cash from Financing Activities	20.98	343.43	-64.34	-112.88	247.29
Net Cash Inflow / Outflow	-56.08	93.92	-69.08	11.28	-14.09

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
ROCE (%)	27.50	25.25	24.61	18.04	28.50
ROE (%)	28.49	21.30	19.61	14.45	22.72
ROA (%)	19.48	11.42	16.31	12.66	31.25
EBIT Margin (%)	28.03	15.68	29.25	28.29	32.18
Net Margin (%)	20.72	10.47	22.63	23.29	26.06
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Revenue Growth (%)	78.33	18.36	7.93	-6.72	23.56
EBIT Growth (%)	303.07	30.43	19.88	-26.64	12.00
Net Profit Growth (%)	182.61	32.39	21.66	-24.38	20.07
EPS Growth (%)	277.72	36.68	25.42	-21.99	50.65
Book Value Growth (%)	22.95	11.36	18.43	11.27	79.97

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Price / Earnings	55.41	35.71	27.06	51.78	71.34
Price / Book Value	13.64	7.05	4.83	6.94	14.67
Dividend Yield (%)	0.16	0.19	0.36	0.55	0.13
EV/EBITDA	35.94	19.51	19.20	35.97	58.34
Market Cap (₹ Cr)	15,412.11	30,257.56	11,956.86	10,627.92	6,690.53

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Debt to Equity	0.09	0.05	0.00	0.00	0.04
Short term debt to equity ratio	--	0.16	--	--	0.12
Current Ratio	2.09	1.43	5.21	7.39	3.09
Quick Ratio	1.37	0.82	3.85	5.46	2.02
Interest Coverage	26.41	10.36	148.49	1,386.30	30.94

	Neuland Lab	Emcure Pharmaceuticals	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Debtors to sales (%)	22.82	26.46	41.42	41.52	33.68
Asset Turnover	0.93	1.09	0.70	0.52	1.15
Receivable days	77.32	88.68	144.58	169.86	115.16
Inventory Days	80.83	84.11	96.67	97.92	96.15
Payable days	125.94	176.65	135.45	159.68	106.08
Cash Conversion Cycle	32.22	-3.86	105.80	108.11	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.